Neuroendocrine Tumours Clinical Trial
Official title:
Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours
The objective of the PRELUDE study is to describe the use of lanreotide Autogel® (LAN ATG) combined with Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of progressive neuroendocrine tumours located in the lung or in the digestive system as there is currently limited data on these treatments used together for these types of neuroendocrine tumours.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00323076 -
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT02075606 -
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
|
Phase 4 | |
| Completed |
NCT00326469 -
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
|
Phase 2 | |
| Completed |
NCT01840449 -
Somatuline Predictive Factors in Acromegaly and NET
|
||
| Completed |
NCT02698410 -
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
|
Phase 2 | |
| Active, not recruiting |
NCT02923934 -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
|
Phase 2 | |
| Completed |
NCT01673906 -
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
|
Phase 2 | |
| Active, not recruiting |
NCT04579679 -
Open-Label Surufatinib in European Patients With NET
|
Phase 2 |